Reinforced absorbable synthetic matrix for hemostatic applications

• US 8,383,147 B2
• Filed: 08/22/2012
• Issued: 02/26/2013
• Est. Priority Date: 05/17/2010
• Status: Active Grant

• Current Assignee: Ethicon Incorporated (Johnson & Johnson)
• Original Assignee: Ethicon Incorporated (Johnson & Johnson)
• Inventors: Shetty, Dhanuraj S., Moloye-Olabisi, Olajompo, Van Holten, Robert W., Zhong, Degang
• Primary Examiner(s): ARNOLD, ERNST V
• Application Number:
  US13/591,501
• Publication Number:
  US 20120315316A1
• Time in Patent Office: 188 Days
• Field of Search: None
• US Class Current: 424/444
• CPC Class Codes: A61K 38/363 Fibrinogen
• CPC Class Codes: A61K 38/4833 Thrombin (3.4.21.5)
• CPC Class Codes: A61L 15/26 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof A61L15/225 takes precedence
• CPC Class Codes: A61L 15/44 Medicaments
• CPC Class Codes: A61L 2300/418 Agents promoting blood coagulation, blood-clotting agents, embolising agents
• CPC Class Codes: A61L 2400/04 Materials for stopping bleeding
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

The present invention is directed to a reinforced absorbable hemostat comprising at least one hemostatic agent in a single layer of nonwoven synthetic fabric having a mixture of compressed fiber staples of a polyglycolide/polylactide copolymer and a polydioxanone.

Claims

1. A method for treating a wound or tissue comprising applying a synthetic hemostatic fabric comprising at least one hemostatic agent in a non-woven layer of a first absorbable fabric that comprises polyglycolide/polylactide copolymer and a second absorbable fabric that comprises polydioxanone, wherein both fabrics are in staple form.

2. The method of claim 1, where the first absorbable fabric consists essentially of a copolymer of glycolide/lactide at a 90/10 mol/mol composition.

3. The method of claim 2, where the first absorbable fabric comprises of staple having a length from about 0.75 to 2.5 inches.

4. The method of claim 1 that is substantially free of any oxidized polysaccharide material and the hemostatic agent comprises thrombin.

5. The method of claim 1, where the staple is crimped.

6. The method of claim 4, where the second absorbable fabric comprises of staple having a length from 0.75 to 2.5 inches.

7. The method of claim 6, where the staple is crimped.

8. The method of claim 4, where the hemostatic agent further comprises fibrinogen.

9. The method of claim 1, where the weight ratio of the first fabric staples to the second fabric staples is 70:

30.

10. The method of claim 9, where the mixture of the staples is compacted to a thickness of about 1.5 mm.

11. The method of claim 10, where the mixture of the staples is compacted to a density of about 100 mg/cc.

12. A method according to claim 1 wherein the medical device provides hemostasis when applied to a tissue or wound requiring hemostasis.